ravulizumab   Click here for help

GtoPdb Ligand ID: 10168

Synonyms: ALXN-1210 | ALXN1210 | ravulizumab-cwvz | Ultomiris®
Approved drug Immunopharmacology Ligand
ravulizumab is an approved drug (FDA (2018), EMA (2019))
Compound class: Antibody
Comment: Ravulizumab (ALXN1210; Ultomiris) is a humanized monoclonal antibody that binds to human complement component C5. It was developed by Alexion as a next-generation anti-C5 therapy for paroxysmal nocturnal hemoglobinuria (PNH) that was engineered from their already approved PNH agent eculizumab (Soliris), but was designed to have an inherently longer circulating half-life so as to extend dosing intervals to once/month [3].
Peptide sequence and secondary structural information for this antibody are available from its IMGT/mAb-DB record.
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2018), EMA (2019))
International Nonproprietary Names Click here for help
INN number INN
10659 ravulizumab
Synonyms Click here for help
ALXN-1210 | ALXN1210 | ravulizumab-cwvz | Ultomiris®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 674
Other databases
GtoPdb PubChem SID 381118878
Search PubMed clinical trials ravulizumab
Search PubMed titles ravulizumab
Search PubMed titles/abstracts ravulizumab